Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

93 clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy across international registries, including 29 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — RECRUITING · PHASE1
• A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — RECRUITING · PHASE3
• Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — RECRUITING · PHASE2
• A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — RECRUITING · PHASE3
• A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — RECRUITING · PHASE3
• A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy — RECRUITING · PHASE3
• CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases — RECRUITING · PHASE1
• Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. — RECRUITING · PHASE1
• A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy — RECRUITING · PHASE3
• Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease — RECRUITING · NA
• Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP — RECRUITING
• IVIG vs SCIG in CIDP — RECRUITING · PHASE1
• Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — RECRUITING
• Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders — RECRUITING
• PHASE 3, RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY STUDY EVALUATING THE EFFICACY AND SAFETY OF INTRAVENOUS EMPASIPRUBART VERSUS INTRAVENOUS IMMUNOGLOBULIN IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY — RECRUITING · PHASE3
• The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. — RECRUITING · NA
• Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study — RECRUITING
• A PHASE 2, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF TAK-411 IN ADULT SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (THE CASCA STUDY) — RECRUITING · PHASE2
• Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility. — RECRUITING
• Hizentra® in Inflammatory Neuropathies - pHeNIx Study — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY EVALUATING EFFICACY AND SAFETY OF RILIPRUBART VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN PARTICIPANTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY — RECRUITING · PHASE3
• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF RILIPRUBART IN PARTICIPANTS WITH REFRACTORY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY — RECRUITING · PHASE3
• PHASE 2/3, MULTISTAGE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PARALLEL GROUP WITHDRAWAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) — RECRUITING · PHASE2
• Intravenous immunoglobulin (IVIg)- impact of serum IgG peak-through differences for maintaining anti-inflammatory pathways in CIDP — RECRUITING
• LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/HYQVIA) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) — RECRUITING
• PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF THREE DIFFERENT DOSAGES OF NEWGAM IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLY(RADICULO)NEUROPATHY (PROCID TRIAL) — RECRUITING · PHASE3
• A PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/HYQVIA) AND IMMUNE GLOBULIN INFUSION (HUMAN), 10% (GAMMAGARD LIQUID/KIOVIG) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) — RECRUITING · PHASE3
• Intravenous immunoglobulin and intravenous methylprednisolone as optimal first line treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) — ACTIVE_NOT_RECRUITING · PHASE3
• A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) — COMPLETED · PHASE3
• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — TERMINATED · PHASE3
• To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP — TERMINATED · PHASE2
• An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — TERMINATED · PHASE2
• NT-3 Levels and Function in Individuals With CMT — TERMINATED
• A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — TERMINATED · PHASE2
• A Phase 3, randomized, double-blind study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy — TERMINATED · PHASE3
• Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP. — TERMINATED · NA
• Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — TERMINATED · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF INEBILIZUMAB IN PARTICIPANTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY — NOT_YET_RECRUITING · PHASE3
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC — COMPLETED · PHASE4
• Open-label Extension of the ARGX-113-1802 Trial to Investigate the Longterm Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — TERMINATED · PHASE2
• Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — OTHER
• A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — OTHER · PHASE2
• Rituximab-induced remission in CIDP (ReCIX study) — TERMINATED · PHASE3
• Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases — ACTIVE_NOT_RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF EMPASIPRUBART IV IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY — NOT_YET_RECRUITING · PHASE3
• A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — OTHER · PHASE2
• An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — TERMINATED

Refine this search